The upper bound on medicine's contribution to 20th-century life expectancy

framework · David Wootton

"If one thinks of the vast investment in research laboratories, hospitals, drug companies, and general practitioners dedicated to increasing life expectancy in the period between 1950 and 1980, it is striking that the result was at best only equivalent to the conquest of smallpox twice over."
Wootton, Bad Medicine (Oxford University Press, 2006), p. 275 (Chapter 14, 'A Few of Us Owe Our Lives to Modern Medicine').

SUMMARY

Wootton's quantitative claim is that medicine's contribution to the 20th-century increase in life expectancy is in the range of 12 to 20 percent of the total gain, with the balance attributable to sanitation, nutrition, and behavioural change. The principal source of the population-level gain in life expectancy in the English data 1680 to 1850 is smallpox inoculation and vaccination (Wootton p. 275, with Jenner's 1796 vaccination as the load-bearing intervention). Domestic micro-sanitation (potty training, hand-washing, fly control, food covering) c. 1907 to 1930s accounted for the persistent infant-mortality gap that piped water and sewers c. 1850 to 1900 had not closed (p. 278 to 280). Fogel's height-and-life-expectancy work identifies improved fetal and childhood nutrition as the largest single contributor to life-expectancy gains since 1875 (p. 281 to 282). The framework's operational claim for elite-longevity medicine is that the entire class of intervention is operating in a domain (medical contribution to life expectancy) that has accounted for no more than 20 percent of the historical gain, that the residual room for improvement in any one component of that 20 percent is small, and that the marginal life-expectancy return on the contemporary elite-longevity intervention class is bounded above by the residual room for improvement in the most successful medical intervention class of the relevant era (typically antibiotics, vaccines, or anti-hypertensives) and is bounded below by zero.

APPLIES TO CASES

APPLIES TO INTERVENTIONS

SOURCES

Bad Medicine: Doctors Doing Harm Since Hippocrates

NOTES

The framework is the archive’s quantitative anchor for the proposition that elite-longevity medicine cannot, as a class, deliver the population-level life-extension benefits that its marketing claims. Wootton’s analysis identifies the historical upper bound on what any clinical intervention can deliver in life-expectancy terms (Jenner’s smallpox vaccination, responsible for approximately one-third of the 1680 to 1850 English life-expectancy gain) and the historical aggregate ceiling on medicine’s contribution to 20th-century gains (12 to 20 percent of the total). The implication for elite-longevity practice is that no contemporary intervention can plausibly exceed Jenner’s per-person life-expectancy contribution, and no contemporary intervention class can plausibly exceed the 20 percent aggregate ceiling. The TPE-IVIG protocol, the cellular therapy practice, the testicular extract practice, and the monkey-gland graft practice were each, in their period, claimed by their practitioners to be transformative life-extension interventions. None has been demonstrated to deliver a hard-endpoint life-expectancy benefit at all, and none plausibly could have approached the per-person life-expectancy gain delivered by basic smallpox vaccination, basic municipal sanitation, or basic childhood nutrition. The framework is the citation for any archive claim about the plausible upper bound on what elite-longevity practice can deliver.”